Form 4: Pfizer CEO Albert Bourla Acquires Additional Phantom Stock Units

Pfizer Inc. Chairman and CEO Albert Bourla has acquired 24 additional phantom stock units, valued at $24.54 each, as part of a deferred compensation plan.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc. (PFE), acquired 24 phantom stock units on June 13, 2025.
• Each phantom unit represents one phantom share of common stock.
• The acquisition was made at a price of $24.54 per unit.
• These units were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• The units are settled in cash following the reporting person's separation from service.
• The reporting person has the option to transfer these units into an alternative investment account at any time.
• Following this transaction, Mr. Bourla beneficially owns 718,048 phantom stock units.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged plan.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued executive alignment with the company's performance through a compensation plan, but it's a routine, small transaction not indicative of significant new developments.

Positives

• The acquisition of additional phantom stock units by the Chairman and CEO, Albert Bourla, indicates continued alignment of management's interests with shareholder value, as these units are tied to the company's stock performance.
• The transaction was conducted under a Rule 10b5-1(c) plan, suggesting a pre-planned and routine compensation event rather than a discretionary market purchase or sale.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Pfizer Inc.'s future financial performance or strategic outlook.

Industry Context

This filing represents a routine executive compensation disclosure within the pharmaceutical industry, where deferred compensation plans, including phantom stock units, are common mechanisms to align executive incentives with long-term company performance and shareholder interests. Such plans are standard practice for large, established biopharmaceutical companies like Pfizer.

Stakeholder Impact

• Shareholders: The acquisition of phantom stock units by the CEO reinforces management's alignment with shareholder interests, as the value of these units is tied to the company's stock performance. However, the small number of units acquired in this specific transaction is unlikely to have a material impact on the company's overall share structure or valuation.

Key Dates

Keywords

Pfizer, PFE, Albert Bourla, SEC Form 4, Insider Trading, Phantom Stock Units, Deferred Compensation, Executive Compensation, Rule 10b5-1, Biopharmaceutical, Pharmaceutical